MedImmune v. Genentech — Patent Licensees Can Seek Declaratory Judgment Without Breaching License

Background

MedImmune manufactures Synagis, a widely used drug that prevents respiratory tract infections in premature infants. In 1997, MedImmune entered into a patent license agreement with Genentech covering, among other things, a patent related to chimeric antibody production. MedImmune agreed to pay royalties on Synagis sales; Genentech agreed not to sue MedImmune for infringement of the licensed patents.

In 2001, Genentech notified MedImmune that it believed Synagis fell within the scope of a new, related patent and demanded royalties. MedImmune believed the patent was invalid and that Synagis did not infringe it, but the stakes were enormous: if MedImmune stopped paying royalties and was wrong, it faced treble damages in an infringement suit that could threaten the company’s existence. Faced with that coercive situation, MedImmune continued paying royalties “under protest” while simultaneously filing suit in federal court seeking a declaration that the patent was invalid and not infringed.

The district court dismissed for lack of jurisdiction, reasoning that because MedImmune was paying royalties and thus not in breach, there was no “actual controversy” between the parties as required by the Declaratory Judgment Act. The Ninth Circuit affirmed. The question before the Supreme Court was whether a licensee in good standing — not in breach of its license — can challenge the underlying patent’s validity or scope.

The Court’s Holding

Justice Scalia, writing for an 8-1 majority, reversed and held that MedImmune had standing to bring its declaratory judgment action. The Court applied the long-standing test for an “actual controversy” under the Declaratory Judgment Act: whether the facts alleged, under all the circumstances, show a substantial controversy between parties having adverse legal interests, of sufficient immediacy and reality to warrant a declaration.

The Court found that test satisfied. Genentech had threatened to sue if MedImmune did not pay royalties on the new patent; MedImmune faced a genuine dilemma between paying royalties it believed were not owed and risking catastrophic infringement liability if it stopped. The fact that MedImmune chose the prudent path of paying while challenging was no reason to strip it of its day in court. Requiring a licensee to breach its agreement and expose itself to a lawsuit before it can seek a declaration would force parties into an “agonizing choice” that the Declaratory Judgment Act was designed to eliminate.

The Court explicitly rejected the argument that the license agreement — which gave MedImmune some protection from suit — eliminated the controversy. The controversy was real because Genentech claimed MedImmune owed royalties on the disputed patent, and MedImmune disputed that obligation. Those are adverse legal interests sufficient to support jurisdiction.

Key Takeaways

• A patent licensee who continues paying royalties under protest retains standing to seek a declaratory judgment that the underlying patent is invalid or not infringed — the licensee need not breach the license to create an actual controversy.
• The Declaratory Judgment Act is designed to prevent parties from being forced into the “agonizing choice” between paying for rights they do not owe and facing ruinous litigation.
• Patent holders can no longer use licensing agreements as a shield against validity challenges by licensees who disagree with the scope or validity of the licensed patent.
• Post-MedImmune, patent licensees frequently use declaratory judgment actions to contest patents without first terminating their licenses, changing the dynamics of patent licensing negotiations.

Why It Matters

Before MedImmune, patent holders had a powerful tool: once a licensee signed a license, it was difficult for the licensee to challenge the patent’s validity — the Federal Circuit had held in Gen-Probe v. Vysis that a licensee in good standing lacked standing to challenge the patent. This created a one-sided dynamic: licensees were locked in, paying royalties even if they believed the patent was invalid, because challenging it required breaching the license and risking a lawsuit that might dwarf the royalty payments.

The MedImmune decision fundamentally changed patent licensing. Now, licensees can challenge patents they are licensed under while maintaining the license as protection against infringement liability. This has made patents somewhat less valuable as licensing leverage — if a licensee can both pay reasonable royalties and challenge the patent at the same time, the royalty is no longer a complete settlement of the dispute. The decision has also fueled the growth of inter partes review and other post-grant proceedings at the USPTO as alternatives to court-based validity challenges.